Advanced in Breast Cancer

Dr. Philip J. Stella

Oncology | Hematology

5301 E Huron River Dr, Ste C-139,

Ypsilanti, MI

Clinical Trials:Currently Recruiting for 10 Trials

Accepting New Patients

Advanced in Breast Cancer

5301 E Huron River Dr, Ste C-139,

Ypsilanti, MI

OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Philip Stella is an Oncologist and a Hematologist in Ypsilanti, Michigan. Dr. Stella is rated as an Advanced provider by MediFind in the treatment of Breast Cancer. His top areas of expertise are Lung Cancer, Colorectal Cancer, Pancreatic Cancer, and Pleuropulmonary Blastoma. Dr. Stella is currently accepting new patients.

His clinical research consists of co-authoring 40 peer reviewed articles and participating in 77 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 10 clinical trials in the study of Breast Cancer.

Specialties

Oncology

Hematology

Licenses

Internal Medicine in MI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield

Humana

HMO
INDEMNITY
POS
PPO

Locations

5301 E Huron River Dr, Ste C-139, Ypsilanti, MI 48197

Call: 734-712-1000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

75 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: December 17, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

Cancer Moonshot Biobank Research Protocol

Enrollment Status: Recruiting

Publish Date: December 17, 2025

Intervention Type: Procedure, Other

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Recruiting

Publish Date: December 17, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Bevacizumab, Osimertinib

Study Phase: Phase 3

RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial

Enrollment Status: Recruiting

Publish Date: December 17, 2025

Intervention Type: Procedure, Radiation, Drug

Study Drug: Atezolizumab

Study Phase: Phase 2/Phase 3

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations

Enrollment Status: Recruiting

Publish Date: December 12, 2025

Intervention Type: Drug

Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib

Study Phase: Phase 2

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)

Enrollment Status: Recruiting

Publish Date: December 05, 2025

Intervention Type: Drug

Study Drug: Screening Platform

Study Phase: Phase 2/Phase 3

Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Enrollment Status: Recruiting

Publish Date: November 28, 2025

Intervention Type: Procedure, Drug

Study Phase: Phase 2

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer: The M&M Study

Enrollment Status: Recruiting

Publish Date: November 06, 2025

Prospective Observational Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Enrollment Status: Recruiting

Publish Date: October 08, 2025

Intervention Type: Other, Drug

Study Drug: Carvedilol

Study Phase: Phase 3

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Enrollment Status: Recruiting

Publish Date: February 28, 2025

Intervention Type: Other

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients With Germline BRCA1 or BRCA2 Mutations

Enrollment Status: Active_not_recruiting

Publish Date: December 17, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Olaparib, Pembrolizumab

Study Phase: Phase 2

A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma

Enrollment Status: Active_not_recruiting

Publish Date: December 17, 2025

Intervention Type: Other, Procedure, Drug

Study Drugs: Olaparib, Temozolomide

Study Phase: Phase 2

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Enrollment Status: Active_not_recruiting

Publish Date: December 17, 2025

Intervention Type: Other, Procedure, Biological, Drug

Study Phase: Not Applicable

A Phase II Study of AMG 510 in Participants With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)

Enrollment Status: Active_not_recruiting

Publish Date: December 05, 2025

Intervention Type: Drug

Study Drug: Sotorasib

Study Phase: Phase 2

Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: December 04, 2025

Intervention Type: Other, Drug

Study Drug: Erlotinib Hydrochloride

Study Phase: Phase 3

A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Other, Drug

Study Drugs: Docetaxel, Trametinib

Study Phase: Phase 2

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Enrollment Status: Active_not_recruiting

Publish Date: December 02, 2025

Intervention Type: Other, Biological, Procedure

Study Drug: Nivolumab

Study Phase: Phase 3

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Drug, Other

Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy

Study Phase: Phase 3

EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis

Enrollment Status: Active_not_recruiting

Publish Date: November 25, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed

Study Phase: Phase 3

Longitudinal Assessment of Financial Burden in Patients With Colon or Rectal Cancer Treated With Curative Intent

Enrollment Status: Active_not_recruiting

Publish Date: November 24, 2025

Intervention Type: Other

A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

Molecular Analysis for Therapy Choice (MATCH)

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib

Study Phase: Phase 2

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Biological, Other

Study Drug: Nivolumab

Study Phase: Phase 3

A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients With Previously Treated Non-Squamous NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Drug, Biological

Study Drugs: Cabozantinib S-malate, Docetaxel, Gemcitabine Hydrochloride, Nab-paclitaxel, Nivolumab, Paclitaxel, Ramucirumab

Study Phase: Phase 2

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Other, Drug, Procedure, Radiation

Study Drug: Atezolizumab

Study Phase: Phase 3

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium

Study Phase: Phase 3

STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma With Pembrolizumab, a Phase III Trial

Enrollment Status: Active_not_recruiting

Publish Date: November 17, 2025

Intervention Type: Procedure, Other, Radiation, Biological

Study Drug: Pembrolizumab

Study Phase: Phase 3

Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastatectomy

Enrollment Status: Active_not_recruiting

Publish Date: November 14, 2025

Intervention Type: Procedure, Drug, Other

Study Drug: Pazopanib Hydrochloride

Study Phase: Phase 3

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Enrollment Status: Active_not_recruiting

Publish Date: November 13, 2025

Intervention Type: Other, Procedure

Study Phase: Phase 3

Exceptional Responders Pilot Study: Molecular Profiling of Tumors From Cancer Patients Who Are Exceptional Responders

Enrollment Status: Active_not_recruiting

Publish Date: October 20, 2025

Intervention Type: Other

A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)

Enrollment Status: Active_not_recruiting

Publish Date: September 18, 2025

Intervention Type: Drug, Other, Biological

Study Drugs: Afatinib Dimaleate, Cetuximab

Study Phase: Phase 2/Phase 3

NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study

Enrollment Status: Active_not_recruiting

Publish Date: September 10, 2025

Intervention Type: Procedure

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma

Enrollment Status: Active_not_recruiting

Publish Date: September 09, 2025

Intervention Type: Procedure, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 2

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Enrollment Status: Active_not_recruiting

Publish Date: September 08, 2025

Intervention Type: Other, Behavioral

Study Phase: Phase 3

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol

Enrollment Status: Active_not_recruiting

Publish Date: August 13, 2025

Intervention Type: Drug

Study Drugs: Alectinib, Brigatinib, Carboplatin, Ceritinib, Cisplatin, Crizotinib, Ensartinib, Lorlatinib, Pemetrexed

Study Phase: Phase 2

A Phase II Study of LOXO-292 in Patients With RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: July 11, 2025

Intervention Type: Drug

Study Drug: Selpercatinib

Study Phase: Phase 2

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

Enrollment Status: Active_not_recruiting

Publish Date: July 08, 2025

Intervention Type: Drug, Procedure, Radiation

Study Drug: Durvalumab

Study Phase: Phase 2

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

Enrollment Status: Completed

Publish Date: July 03, 2025

Intervention Type: Drug, Biological

Study Drugs: Carboplatin, Cisplatin, Etoposide, Nivolumab

Study Phase: Phase 2

The National Myelodysplastic Syndromes Natural History Study

Enrollment Status: Active_not_recruiting

Publish Date: July 02, 2025

Intervention Type: Other

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice)

Enrollment Status: Active_not_recruiting

Publish Date: June 13, 2025

Intervention Type: Other, Drug

Study Drugs: Pembrolizumab, Pemetrexed, Carboplatin

Study Phase: Phase 2

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)

Enrollment Status: Completed

Publish Date: May 23, 2025

Intervention Type: Other, Radiation, Drug

Study Drug: Cisplatin

Study Phase: Phase 3

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)

Enrollment Status: Active_not_recruiting

Publish Date: May 21, 2025

Intervention Type: Other, Biological

Study Drugs: Ipilimumab, Nivolumab

Study Phase: Phase 3

A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)

Enrollment Status: Completed

Publish Date: May 21, 2025

Intervention Type: Drug

Study Drug: Rucaparib

Study Phase: Phase 2

A Randomized Phase III Double Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes

Enrollment Status: Active_not_recruiting

Publish Date: May 15, 2025

Intervention Type: Other, Dietary supplement

Study Phase: Phase 3

Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)

Enrollment Status: Active_not_recruiting

Publish Date: May 07, 2025

Intervention Type: Drug, Other

Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin

Study Phase: Phase 2/Phase 3

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Enrollment Status: Active_not_recruiting

Publish Date: March 30, 2025

Intervention Type: Drug

Study Phase: Phase 3

A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer

Enrollment Status: Active_not_recruiting

Publish Date: March 19, 2025

Intervention Type: Drug

Study Drugs: TAK-700, Bicalutamide

Study Phase: Phase 3

Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of an Efficient Pre-Surgical Toolkit (OPTI-Surg)

Enrollment Status: Active_not_recruiting

Publish Date: February 21, 2025

Intervention Type: Other

Study Phase: Not Applicable

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Enrollment Status: Active_not_recruiting

Publish Date: January 13, 2025

Intervention Type: Other, Dietary supplement, Drug

Study Drugs: Bevacizumab, Oxaliplatin, Leucovorin calcium, Fluorouracil, Irinotecan hydrochloride, Irinotecan

Study Phase: Phase 3

A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

Enrollment Status: Active_not_recruiting

Publish Date: January 13, 2025

Intervention Type: Radiation, Procedure

Study Phase: Phase 3

View 40 Less Clinical Trials

40 Total Publications

Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer.

Journal: Breast cancer research and treatment

Published: August 13, 2021

View All 40 Publications

Similar Doctors

Elite in Breast Cancer

Dr. Norah L. Henry

Oncology | Hematology

Elite in Breast Cancer

Dr. Norah L. Henry

Oncology | Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr,

Ann Arbor, MI

(4.1 miles away)

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Norah Henry is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Henry is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Salpingo-Oophorectomy. Dr. Henry is currently accepting new patients.

Elite in Breast Cancer

Dr. Sofia D. Merajver

Oncology

Elite in Breast Cancer

Dr. Sofia D. Merajver

Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr,

Ann Arbor, MI

(4.1 miles away)

Languages Spoken:

English

See accepted insurances

Accepting New Patients

Offers Telehealth

Sofia Merajver is an Oncologist in Ann Arbor, Michigan. Dr. Merajver is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, and Angiosarcoma. Dr. Merajver is currently accepting new patients.

Elite in Breast Cancer

Dr. Aki Morikawa

Oncology | Hematology | Hematology Oncology

Elite in Breast Cancer

Dr. Aki Morikawa

Oncology | Hematology | Hematology Oncology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr,

Ann Arbor, MI

(4.1 miles away)

Languages Spoken:

English, Japanese

See accepted insurances

Accepting New Patients

Offers Telehealth

Aki Morikawa is an Oncologist and a Hematologist in Ann Arbor, Michigan. Dr. Morikawa is rated as a Distinguished provider by MediFind in the treatment of Breast Cancer. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Angiosarcoma. Dr. Morikawa is currently accepting new patients.

VIEW MORE BREAST CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stella's expertise for a condition

ConditionClose